update, page-14

Hi Primaus72

Just to confirm the 6 week data is the same data and therefore same patients from the 2 phase 3 trials. It is just the first check point from the 2 trials data set.
You will see the chart in the investor presentation they did in June.


PXS just need to prove that the data first taken at 6 weeks is a reliable indication of how you respond over the next 6 months. If they can do that then it removes all arguments in so far as

1) You agree with the EMEA what the improvement needs to be at 6 weeks to stay on the drug. This can be FEV1 of any % or a mixture of FEV1 and reduced infections.

2) It removes all age variabilty as only those who respond to point 1 above stay on the drug.

3) Safety issues are reduced because again non responders drop out after 6 weeks treatment so the benefit of those who stay on the drug outweighs what appears really to be non safety issues.

Cheers